2 results
Approved WMOCompleted
Primary Safety Objective: To describe the safety profile of 20vPnC
Approved WMOPending
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and pertuzumab as maintenance therapy in subjects with advanced HER2+ breast cancer who have had prior treatment with a taxane, trastuzumab, and pertuzumab.